Sébastien Redon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sébastien Redon has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Patrice Vanelle
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
15 shared publications - Julie Broggi
Aix Marseille Univ., CNRS, ICR - UMR 7273, 13005, Marseille, France
8 shared publications Patrice Vanelle
7 shared publications- Yann Bretonnière
LCH, UMR 5182 CNRS‐ENS Lyon‐Université Lyon I France
6 shared publications Anne Roly Obah Kosso
5 shared publications- Youssef Kabri
Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
5 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Towards novel thiazolidine-2,4-diones. Synthesis, anticancer activity, DFT, and molecular docking
Two series of 3-substituted (Z)-5-(3,4,5-trimethoxybenzylidene)thiazolidine-2,4-dione derivatives were designed, synthesized, and evaluated for their anticancer potential. The first series (9a-f) incorporates carbamate moieties, whereas the second series (10a-e and 11a,b) contains urea functionalities. The synthetic route involved hydrolysis of the ester 4 into the corresponding acid 6, followed by conversion to the acid azide intermediate 8, and subsequent Curtius rearrangement in the presence of alcohols or amines to afford the target compounds. The antiproliferative activity of the synthesized derivatives was assessed against a panel of human cancer cell lines (MCF-7, MDA-MB-231, A2780, A2780cis, and K562), as well as the non-tumorigenic HaCaT cell line, using cisplatin as a reference drug. Several derivatives demonstrated promising cytotoxicity; in particular, the six compounds (9c, 9e, 9f, 10a, 10b, and 10c) exhibited IC50 values below 20 µM. Notably, compounds 9c, 9e, 10a, and 10b showed pronounced selectivity toward the aggressive triple-negative breast cancer MDA-MB-231 cell line, underscoring this scaffold as a promising platform for anticancer drug development. The urea derivatives 10a and 10b demonstrated superior activity compared with the carbamate analogues 9c and 9e. Compound 10b exhibited the highest activity (IC50 = 6.02±0.91 µM) and appeared as an MDA-MB-231 hit compound. Computational investigations, including DFT calculations and molecular docking, supported the experimental findings and suggested a multitarget mechanism of action.
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTowards novel thiazolidine-2,4-diones. Synthesis, anticancer activity, DFT, and molecular docking
Two series of 3-substituted (Z)-5-(3,4,5-trimethoxybenzylidene)thiazolidine-2,4-dione derivatives were designed, synthesized, and evaluated for their anticancer potential. The first series (9a-f) incorporates carbamate moieties, whereas the second series (10a-e and 11a,b) contains urea functionalities. The synthetic route involved hydrolysis of the ester 4 into the corresponding acid 6, followed by conversion to the acid azide intermediate 8, and subsequent Curtius rearrangement in the presence of alcohols or amines to afford the target compounds. The antiproliferative activity of the synthesized derivatives was assessed against a panel of human cancer cell lines (MCF-7, MDA-MB-231, A2780, A2780cis, and K562), as well as the non-tumorigenic HaCaT cell line, using cisplatin as a reference drug. Several derivatives demonstrated promising cytotoxicity; in particular, the six compounds (9c, 9e, 9f, 10a, 10b, and 10c) exhibited IC50 values below 20 µM. Notably, compounds 9c, 9e, 10a, and 10b showed pronounced selectivity toward the aggressive triple-negative breast cancer MDA-MB-231 cell line, underscoring this scaffold as a promising platform for anticancer drug development. The urea derivatives 10a and 10b demonstrated superior activity compared with the carbamate analogues 9c and 9e. Compound 10b exhibited the highest activity (IC50 = 6.02±0.91 µM) and appeared as an MDA-MB-231 hit compound. Computational investigations, including DFT calculations and molecular docking, supported the experimental findings and suggested a multitarget mechanism of action.
- Open Access
Enhancing Antileishmanial Activity of Amidoxime-Based Compounds Bearing a 4,5-Dihydrofuran Scaffold: In Vitro Screening Against Leishmania amazonensis
Leishmaniasis, a protozoan disease affecting humans, exposes significant shortcomings in current treatments. In continuation to our previous findings on amidoxime-based antileishmanial compounds bearing a 4,5-dihydrofuran scaffold, twelve new amidoxime derivatives substituted at position 3 with an amide bearing a nitrogen heterocycle were synthesized. This series was designed to replace the sulfone and aryl group on a previously reported HIT. The synthesis of these compounds involved the following three-step pathway: manganese (III) acetate-based cyclization of a β-ketoester, followed by amidation with LiHMDS and a final reaction with hydroxylamine. Three of them, containing either bromine, chlorine, or methyl substitutions and featuring a pyridine moiety, showed an interesting toxicity–activity relationship in vitro. They exhibited IC50 values of 15.0 µM, 16.0 µM, and 17.0 µM against the promastigote form of the parasite and IC50 values of 0.5 µM, 0.6 µM, and 0.3 µM against the intracellular amastigote form, respectively. A selectivity index (SI) greater than 300 was established between the cytotoxic concentrations (in murine macrophages) and the effective concentrations (against the intracellular form of Leishmania amazonensis). This SI is at least seventy times higher than that observed for Pentamidine and twenty-five times higher than that observed for the reference HIT, as previously reported.
Open AccessEnhancing Antileishmanial Activity of Amidoxime-Based Compounds Bearing a 4,5-Dihydrofuran Scaffold: In Vitro Screening Against Leishmania amazonensis
Leishmaniasis, a protozoan disease affecting humans, exposes significant shortcomings in current treatments. In continuation to our previous findings on amidoxime-based antileishmanial compounds bearing a 4,5-dihydrofuran scaffold, twelve new amidoxime derivatives substituted at position 3 with an amide bearing a nitrogen heterocycle were synthesized. This series was designed to replace the sulfone and aryl group on a previously reported HIT. The synthesis of these compounds involved the following three-step pathway: manganese (III) acetate-based cyclization of a β-ketoester, followed by amidation with LiHMDS and a final reaction with hydroxylamine. Three of them, containing either bromine, chlorine, or methyl substitutions and featuring a pyridine moiety, showed an interesting toxicity–activity relationship in vitro. They exhibited IC50 values of 15.0 µM, 16.0 µM, and 17.0 µM against the promastigote form of the parasite and IC50 values of 0.5 µM, 0.6 µM, and 0.3 µM against the intracellular amastigote form, respectively. A selectivity index (SI) greater than 300 was established between the cytotoxic concentrations (in murine macrophages) and the effective concentrations (against the intracellular form of Leishmania amazonensis). This SI is at least seventy times higher than that observed for Pentamidine and twenty-five times higher than that observed for the reference HIT, as previously reported.
- Open Access
- 5 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116935
Hit-to-lead optimization of 4,5-dihydrofuran-3-sulfonyl scaffold against Leishmania amazonensis. Effect of an aliphatic moiety
- 5 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116935
Open AccessHit-to-lead optimization of 4,5-dihydrofuran-3-sulfonyl scaffold against Leishmania amazonensis. Effect of an aliphatic moiety
- Open Access
- 16 August 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (36) , 14699-14704
A simple N-heterocyclic carbene for the catalytic up-conversion of aldehydes into stoichiometric super electron donors
Catalytic amounts of 1,3-di(methyl)imidazole-2-ylidene, one of the simplest and most prototypical N-heterocyclic carbenes, can up-convert aldehydes into powerful stoichiometric sources of electrons (Super Electron Donors) for reductive transformations of iodoaryls (Ered < −2 V). In particular, the hydroarylation of 1,1′-diarylethylenes, which may require high temperatures and inherently generate stoichiometric amounts of oxidized waste, was performed at room temperature, with the concomitant formation of esters as oxidized co-products.
- 16 August 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (36) , 14699-14704
Open AccessA simple N-heterocyclic carbene for the catalytic up-conversion of aldehydes into stoichiometric super electron donors
Catalytic amounts of 1,3-di(methyl)imidazole-2-ylidene, one of the simplest and most prototypical N-heterocyclic carbenes, can up-convert aldehydes into powerful stoichiometric sources of electrons (Super Electron Donors) for reductive transformations of iodoaryls (Ered < −2 V). In particular, the hydroarylation of 1,1′-diarylethylenes, which may require high temperatures and inherently generate stoichiometric amounts of oxidized waste, was performed at room temperature, with the concomitant formation of esters as oxidized co-products.
- Open Access
- 17 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
A Simple N-Heterocyclic Carbene for the Catalytic Up-conversion of Aldehydes into Stoichiometric Super Electron Donors
Catalytic amounts of 1,3-di(methyl)imidazol-2-ylidene, one of the simplest and most prototypical N-heterocyclic carbene can up-convert aldehydes into powerful stoichiometric sources of electrons (Super Electron Donors) for reductive transformations of iodoaryls (Ered <-2 V). In particular, the hydroarylation of 1,1’-diarylethylenes, which may require high temperatures and inherently generates stoichiometric amounts of oxidised wastes, was performed at room temperature, with the concomitant formation of esters as oxidated co-products.
- 17 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Simple N-Heterocyclic Carbene for the Catalytic Up-conversion of Aldehydes into Stoichiometric Super Electron Donors
Catalytic amounts of 1,3-di(methyl)imidazol-2-ylidene, one of the simplest and most prototypical N-heterocyclic carbene can up-convert aldehydes into powerful stoichiometric sources of electrons (Super Electron Donors) for reductive transformations of iodoaryls (Ered <-2 V). In particular, the hydroarylation of 1,1’-diarylethylenes, which may require high temperatures and inherently generates stoichiometric amounts of oxidised wastes, was performed at room temperature, with the concomitant formation of esters as oxidated co-products.
- Open Access
- 22 May 2024
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 61 (7) , 1200-1205
Simple and green synthesis of 3‐acyl‐pyrazolo[1,5‐a]pyridines: [3+2] through cycloaddition of N‐aminopyridines on enaminones
A practicable method is described for the synthesis of 3‐acyl‐pyrazolo[1,5‐a]pyridines from N‐aminopyridines and easily available enaminones via a [3+2] cycloaddition. The reactions proceed well with a broad scope, without using additive (base or oxidant).
- 22 May 2024
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 61 (7) , 1200-1205
Open AccessSimple and green synthesis of 3‐acyl‐pyrazolo[1,5‐a]pyridines: [3+2] through cycloaddition of N‐aminopyridines on enaminones
A practicable method is described for the synthesis of 3‐acyl‐pyrazolo[1,5‐a]pyridines from N‐aminopyridines and easily available enaminones via a [3+2] cycloaddition. The reactions proceed well with a broad scope, without using additive (base or oxidant).
- Open Access
4-(5-Benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-2-nitrobenzamide
As part of our ongoing attempt to broaden the applications of the amidoxime moiety as a potential source of new antileishmanial agents, this study focuses on the product 4-(5-Benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-2-nitrobenzamide. This unexpected amide was obtained in an 85% yield as the major product with a conventional amidoxime synthesis protocol (Ethanol/Na2CO3) involving the reaction of hydroxylamine and a nitrile group. The formation of this amide derivative instead of the expected amidoxime can be attributed to two complementary effects: the strong electron effect of the nitro group and the influence of ethanol, a polar protic solvent. Alternatively, the desired amidoxime derivative, 4-(5-benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-N′-hydroxy-2-nitrobenzimidamide, was obtained in an 80% yield by an alternative protocol (DMSO/KOtBu). This original compound, featuring a nitro group in the ortho position to the amidoxime, will be further evaluated, both in the field of medicinal chemistry and in other relevant areas, highlighting an unusual method to access amidoximes from hindered substrates.
Open Access4-(5-Benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-2-nitrobenzamide
As part of our ongoing attempt to broaden the applications of the amidoxime moiety as a potential source of new antileishmanial agents, this study focuses on the product 4-(5-Benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-2-nitrobenzamide. This unexpected amide was obtained in an 85% yield as the major product with a conventional amidoxime synthesis protocol (Ethanol/Na2CO3) involving the reaction of hydroxylamine and a nitrile group. The formation of this amide derivative instead of the expected amidoxime can be attributed to two complementary effects: the strong electron effect of the nitro group and the influence of ethanol, a polar protic solvent. Alternatively, the desired amidoxime derivative, 4-(5-benzyl-3-((4-fluorophenyl)sulfonyl)-5-methyl-4,5-dihydrofuran-2-yl)-N′-hydroxy-2-nitrobenzimidamide, was obtained in an 80% yield by an alternative protocol (DMSO/KOtBu). This original compound, featuring a nitro group in the ortho position to the amidoxime, will be further evaluated, both in the field of medicinal chemistry and in other relevant areas, highlighting an unusual method to access amidoximes from hindered substrates.
- Open Access
Diethyl (5-Benzyl-2-(4-(N′-hydroxycarbamimidoyl)phenyl)-5-methyl-4,5-dihydrofuran-3-yl)phosphonate
As part of our ongoing research into the antileishmanial properties of amidoxime derivatives, we report a preliminary assessment of the antiparasitic properties of a novel compound, diethyl (5-benzyl-2-(4-(N′-hydroxycarbamimidoyl)phenyl)-5-methyl-4,5-dihydrofuran-3-yl)phosphonate. This compound was evaluated in vitro for the first time against the promastigote form of Leishmania amazonensis. Compounds containing both amidoxime and phosphonyl functional groups in dihydrofuran scaffolds are relatively rare, despite the extensive study of this heterocycle in various biological applications. Therefore, this work makes a valuable contribution to the fight against Leishmania spp. as a neglected disease. The cyclized 4,5-dihydrofuran intermediate scaffold was obtained via a three-step synthetic route that had previously been developed for accessing other derivatives, including the sulfone moiety. This synthesis was performed using a manganese-based free radical oxidative method under microwave irradiation. The intermediary 4,5-dihydrofuran, which included a nitrile group, tolerated the subsequent reaction with hydroxylamine hydrochloride, resulting in the formation of the target product. The target compound showed moderate activity in vitro against the promastigote form of L. amazonensis (IC50 = 91.1 µM).
Open AccessDiethyl (5-Benzyl-2-(4-(N′-hydroxycarbamimidoyl)phenyl)-5-methyl-4,5-dihydrofuran-3-yl)phosphonate
As part of our ongoing research into the antileishmanial properties of amidoxime derivatives, we report a preliminary assessment of the antiparasitic properties of a novel compound, diethyl (5-benzyl-2-(4-(N′-hydroxycarbamimidoyl)phenyl)-5-methyl-4,5-dihydrofuran-3-yl)phosphonate. This compound was evaluated in vitro for the first time against the promastigote form of Leishmania amazonensis. Compounds containing both amidoxime and phosphonyl functional groups in dihydrofuran scaffolds are relatively rare, despite the extensive study of this heterocycle in various biological applications. Therefore, this work makes a valuable contribution to the fight against Leishmania spp. as a neglected disease. The cyclized 4,5-dihydrofuran intermediate scaffold was obtained via a three-step synthetic route that had previously been developed for accessing other derivatives, including the sulfone moiety. This synthesis was performed using a manganese-based free radical oxidative method under microwave irradiation. The intermediary 4,5-dihydrofuran, which included a nitrile group, tolerated the subsequent reaction with hydroxylamine hydrochloride, resulting in the formation of the target product. The target compound showed moderate activity in vitro against the promastigote form of L. amazonensis (IC50 = 91.1 µM).
- 27 June 2023
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 34 (14) , 1685-1688
Efficient Synthesis of Aminoquinolinium and Aminoquinazolinium Salt Series: Amination or N-Alkylation First?
The pharmacokinetic properties and, in particular, the poor solubilities of lead drug compounds are often a major impediment to their future clinical development. One common and effective solution is generally to use salt forms. Efficient strategies for the synthesis of quinolinium and quinazolinium salt series with promising therapeutic activities are thus of major interest. This study compares different synthetic routes for the rapid preparation of monomeric and dimeric aminoquinolinium and aminoquinazolinium salts. The advantages and limitations of the different processes, especially the importance of step order, are discussed.
- 27 June 2023
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 34 (14) , 1685-1688
Efficient Synthesis of Aminoquinolinium and Aminoquinazolinium Salt Series: Amination or N-Alkylation First?
The pharmacokinetic properties and, in particular, the poor solubilities of lead drug compounds are often a major impediment to their future clinical development. One common and effective solution is generally to use salt forms. Efficient strategies for the synthesis of quinolinium and quinazolinium salt series with promising therapeutic activities are thus of major interest. This study compares different synthetic routes for the rapid preparation of monomeric and dimeric aminoquinolinium and aminoquinazolinium salts. The advantages and limitations of the different processes, especially the importance of step order, are discussed.